Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Poxel (POXEL) EUR0.02

Sell:€6.24 Buy:€6.32 Change: €0.08 (1.27%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.08 (1.27%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.08 (1.27%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.

Contact details

Imm Le Sunway
259/261 Avenue Jean Jaures
+33 (4) 37372010

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€178.90 million
Shares in issue:
28.50 million
Euronext Paris

Key personnel

  • Pierre Legault
    Chairman of the Board
  • Thomas Kuhn
    Chief Executive Officer, Director
  • Anne Renevot
    Chief Financial Officer
  • Sebastien Bolze
    Chief Operating Officer, Executive Vice President in charge of Project Management, Non Clinical and Manufacturing operations
  • Noah Beerman
    Executive Vice President in charge of Business Development and President of Operations in the United States
  • Pascale Fouqueray
    Executive Vice President, in charge of Clinical Development and Regulatory Affairs
  • Jonae Barnes
    Senior Vice President, Investor Relations and Public Relations
  • Elizabeth Woo
    Senior Vice President, Investor Relations, Public Relations and Corporate Communications
  • Sophie Bozec
    Senior Vice President in charge of R&D Pharmacology and Scientific Communication
  • Takashi Kaneko
    Senior Vice President Medical, President of Poxel Japan K.K

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.